Abstract:Depression is a heterogeneous mental disorder characterized by feelings of sadness and loss of interest that render the subject unable to handle basic daily activities such as sleeping, eating, or working. Neurobiological traits leading to depression include genetic background, early life abuse, life stressors, and systemic and central inflammatory profiles. Several clinical and preclinical reports documented that depression shows an increase in pro-inflammatory markers such as interleukin (IL-)1β, IL-6, IL-12, tumor necrosis factor (TNF), and interferon (IFN)-γ; and a decrease in anti-inflammatory IL-4, IL-10, and transforming growth factor (TGF)-β species. Inflammatory activation may trigger and maintain depression. Dynamic crosstalk between the peripheral immune system and the central nervous system (CNS) such as activated endothelial cells, monocytes, monocyte-derived dendritic cells, macrophages, T cells, and microglia has been proposed as a leading cause of neuroinflammation. Notably, pro-inflammatory cytokines disrupt the hypothalamic-pituitary-adrenal (HPA) axis and serotonergic, noradrenergic, dopaminergic, and glutamatergic neurotransmission. While still under investigation, peripheral cytokines can engage brain pathways and affect the central synthesis of HPA hormones and neurotransmitters through several mechanisms such as activation of the vagus nerve, increasing the permeability of the blood-brain barrier (BBB), altered cytokines transport systems, and engaging toll-like receptors (TLRs) by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). However, physiological mechanisms that favor time-dependent central inflammation before or during illness are not totally understood. This review will provide preclinical and clinical evidence of DAMPs and the BBB permeability as contributors to depression and neuroinflammation. We will also discuss pharmacologic approaches that could potentially modulate DAMPs and BBB permeability for future interventions against major depression.

Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis

The Protective Role Of Neuregulin1-Erbb4 Signaling In A Chronic Social Defeat Stress Model

Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics

Prospective Role of MicroRNAs in Depression

Microglia Sing the Prelude of Neuroinflammation-Associated Depression

Inflammation Mediates Varying Effects in Neurogenesis: Relevance to the Pathogenesis of Brain Injury and Neurodegenerative Disorders

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Omega-3 Fatty Acids and Neuroinflammation in Depression: Targeting Damage-Associated Molecular Patterns and Neural Biomarkers

New Insights into the Pivotal Role of the Amygdala in Inflammation-Related Depression and Anxiety Disorder

Microglia in depression: current perspectives

Neuroimmune Advance in Depressive Disorder

Neuroinflammation and depression: A review

The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death

Neuroinflammation and Neurogenesis in Alzheimer’s Disease and Potential Therapeutic Approaches

Common Cellular and Molecular Mechanisms and Interactions Between Microglial Activation and Aberrant Neuroplasticity in Depression

The role of damage associated molecular pattern molecules (DAMPs) and permeability of the blood-brain barrier in depression and neuroinflammation

Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes

Connexin 43: An Interface Connecting Neuroinflammation to Depression

Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches

Icariin and Icaritin Ameliorated Hippocampus Neuroinflammation Via Mediating HMGB1 Expression in Social Defeat Model in Mice.